Maybe We’ll Win the War Against HIV After All

<a href="http://www.istockphoto.com/photo/painkillers-42194072?st=f62ad4b"> Claudio Ventrella</a>/iStock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


A new study published Tuesday in the journal Clinical Infectious Diseases shows a HIV-prevention treatment may have been successful at preventing new cases of the disease.

The regimen, which is called preexposure prophylaxix (or PrEP), involves administering antiviral medication to those at-risk for contracting HIV—stopping infections before they become permanent. This is the largest evaluation of PrEP, administered daily as a single pill called Truvada, since the Food and Drug Administration approved the drugs in 2012. Also, it’s the first study done outside a clinical setting.

During the course of the 32-month study, researchers at Kaiser Permanente San Francisco Medical Center found no new cases of infection among the 675 patients taking Truvada, most of whom were gay men considered to be at higher risk for contracting HIV.

Critics of the drug have raised concerns that it will pave the way for unsafe sex—much like the accusations against early birth control users. However, health officials and gay rights advocates have overwhelmingly voiced support for its use, saying it may be a promising treatment for preventing the spread of HIV.

Previous studies, conducted in a clinical setting, showed that the drug could stop 92 percent of HIV infections in those taking the pills if they are taken correctly and consistently. Truvada is currently recommended by both the Centers for Disease Control and Prevention and the World Health Organization for at-risk groups, including drug-users, gay and bisexual men as well as anyone who has a HIV-positive partner.

Kaiser researchers, however, emphasized the treatment should be used more widely, and “underscored the need for outreach to others at risk for HIV, including transgender women, heterosexual men and women, and people using injection drugs.”

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate